BE829845A - Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants - Google Patents

Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants

Info

Publication number
BE829845A
BE829845A BE157011A BE157011A BE829845A BE 829845 A BE829845 A BE 829845A BE 157011 A BE157011 A BE 157011A BE 157011 A BE157011 A BE 157011A BE 829845 A BE829845 A BE 829845A
Authority
BE
Belgium
Prior art keywords
hypocholesterolemant
antidiabetic
medicinal products
new pyrimidines
pyrimidines
Prior art date
Application number
BE157011A
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BE829845A publication Critical patent/BE829845A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BE157011A 1975-04-10 1975-06-04 Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants BE829845A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7511154A FR2306697A1 (fr) 1975-04-10 1975-04-10 Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants

Publications (1)

Publication Number Publication Date
BE829845A true BE829845A (fr) 1975-12-04

Family

ID=9153719

Family Applications (1)

Application Number Title Priority Date Filing Date
BE157011A BE829845A (fr) 1975-04-10 1975-06-04 Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants

Country Status (12)

Country Link
US (1) US3984411A (de)
JP (1) JPS51118777A (de)
BE (1) BE829845A (de)
CA (1) CA1036597A (de)
CH (1) CH603626A5 (de)
DE (1) DE2528360A1 (de)
ES (1) ES439017A1 (de)
FR (1) FR2306697A1 (de)
GB (1) GB1502182A (de)
IT (1) IT1036400B (de)
LU (1) LU72743A1 (de)
NL (1) NL7507441A (de)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684005A (en) * 1988-12-07 1997-11-04 Glaxo Wellcome Inc. Pharmacologically active CNS compounds
WO1999024422A1 (en) * 1997-11-05 1999-05-20 Neurosearch A/S Azaring-ether derivatives and their use as nicotinic ach receptor modulators
US7470699B2 (en) 2003-07-11 2008-12-30 Arena Pharmaceuticals, Inc. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7812159B2 (en) 2005-01-10 2010-10-12 Arena Pharamaceuticals, Inc. Processes for preparing aromatic ethers
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US8362248B2 (en) 2005-01-10 2013-01-29 Arena Pharmaceuticals, Inc. Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US11884626B2 (en) 2015-06-22 2024-01-30 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU176972B (hu) * 1977-06-13 1981-06-28 Gyogyszerkutato Intezet Sposob poluchenija novykh proizvodnykh piridazinil-gidrazona
US4648896A (en) * 1982-11-15 1987-03-10 Ciba-Geigy Corporation 2-aryl-4,6-dihalopyrimidines as antidote for protecting cultivated plants from phytotoxic damage caused by herbicides
PL378295A1 (pl) * 2003-02-24 2006-03-20 Arena Pharmaceuticals, Inc. Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu
CA2441775C (en) * 2003-09-23 2004-09-28 Westport Research Inc. Container for holding a cryogenic fluid
JP2008501698A (ja) * 2004-06-04 2008-01-24 アリーナ ファーマシューティカルズ， インコーポレイテッド 代謝の調節因子としての置換アリールおよびヘテロアリール誘導体ならびにそれらに関連する疾患の予防および処置
MX2008003634A (es) * 2005-09-16 2009-10-08 Arena Pharm Inc Moduladores del metabolismo y tratamiento de los trastornos metabolicos.
TW200811140A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
US7642220B2 (en) 2007-08-30 2010-01-05 Dow Agrosciences Llc 2-(substituted phenyl)-6-amino-5-alkoxy, thioalkoxy and aminoalkyl-4-pyrimidinecarboxylates and their use as herbicides
EP3378854B1 (de) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Verfahren zur herstellung von (r)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)essigsäure und salzen davon
ES2879826T3 (es) 2015-06-15 2021-11-23 Nmd Pharma As Compuestos para su uso en el tratamiento de trastornos neuromusculares
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3259623A (en) * 1963-06-14 1966-07-05 Olin Mathieson Process for preparing 2-(secondary amino)-halogenopyrimidines
US3261833A (en) * 1964-10-20 1966-07-19 Smith Kline French Lab 2,4-diamino-6-aminoalkoxy pyrimidines
GB1143167A (en) * 1967-01-25 1969-02-19 Ucb Sa Derivatives of pyrimidine

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684005A (en) * 1988-12-07 1997-11-04 Glaxo Wellcome Inc. Pharmacologically active CNS compounds
WO1999024422A1 (en) * 1997-11-05 1999-05-20 Neurosearch A/S Azaring-ether derivatives and their use as nicotinic ach receptor modulators
EP1357121A1 (de) * 1997-11-05 2003-10-29 Neurosearch A/S Azaring-Ether-Derivate und ihre Verwendung als Nicotinic-Ach-Rezeptormodulatoren
US6756386B1 (en) 1997-11-05 2004-06-29 Neurosearch A/S Azaring-ether derivatives and their use as nicotinic ACh receptor modulators
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7838525B2 (en) 2003-07-11 2010-11-23 Arena Pharmaceuticals, Inc. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8546429B2 (en) 2003-07-11 2013-10-01 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7470699B2 (en) 2003-07-11 2008-12-30 Arena Pharmaceuticals, Inc. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7812159B2 (en) 2005-01-10 2010-10-12 Arena Pharamaceuticals, Inc. Processes for preparing aromatic ethers
US8362248B2 (en) 2005-01-10 2013-01-29 Arena Pharmaceuticals, Inc. Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US11884626B2 (en) 2015-06-22 2024-01-30 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis

Also Published As

Publication number Publication date
JPS51118777A (en) 1976-10-18
CH603626A5 (de) 1978-08-31
DE2528360A1 (de) 1976-10-21
US3984411A (en) 1976-10-05
LU72743A1 (de) 1975-10-08
GB1502182A (en) 1978-02-22
ES439017A1 (es) 1977-06-16
IT1036400B (it) 1979-10-30
FR2306697A1 (fr) 1976-11-05
CA1036597A (fr) 1978-08-15
FR2306697B1 (de) 1979-08-10
NL7507441A (nl) 1976-10-12

Similar Documents

Publication Publication Date Title
FR2306697A1 (fr) Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
BE860049A (fr) Nouveaux benzamides substitues utilisables comme medicaments
FR2294702A1 (fr) Nouvelles 3-cyano pyridines utiles comme medicaments
BE867517A (fr) Derives amines spiranniques, leur preparation et leur utilisation comme medicaments
FR2349566A1 (fr) Nouvelles (1-naphtylalkyl)-amines, leur preparation et leur application comme medicaments
FR2352808A1 (fr) Acides 12-azaprostanoiques utiles comme medicaments
FR2308361A1 (fr) Nouvelles 3,4-dihydrospiro-2h-1,3-benzoxazines utiles comme medicaments
BE854072A (fr) Nouvelles aminopiperidines, leur preparation et leur emploi comme medicament
BE803804A (fr) Nouvelles methylthio-5 pyrimidines utilisables comme medicaments
FR2353540A1 (fr) Nouveaux benzamides applicables comme medicaments
BE883080A (fr) Nouvelles pyrazinobenzodiazepines, leur preparation et leur application comme medicaments
BE824885A (fr) Nouvelles methylthio-5 pyrimidines utilisables comme medicaments antidiabetiques et hypochlolesterolemiants
BE854171A (fr) 2-imino-thiazolidines et thiazolines utiles comme medicaments
BE865404A (fr) 3-amino-6,7-dialcoxy-1h-1,2,4-benzothiadiazine-1-oxydes 1-substitues et leur utilisation comme medicaments
BE868991R (fr) Nouveaux phenylazacycloalcanes utiles comme medicaments
BE832277R (fr) Nouvelles piperazilo-pyrimidines utilisables comme medicaments
FR2315259A1 (fr) Nouvelles amidines terpenoaromatiques utilisables comme medicaments
LU78914A1 (fr) Nouvelles arylenedioxy-bis-dicetones,leur preparation et leur utilisation comme medicaments
FR2316939A1 (fr) Derives de 2-benzopyranone et leur application comme medicaments
BE862038A (fr) 1-amino-alkyl inferieur-3,4-diphenyl-1h-pyrazoles et leur utilisation comme medicaments
FR2322594A1 (fr) Nouvelles 2,3-trans-methylene-15-hydroxy-prostaglandines, leur preparation et leur application comme medicaments
MC1222A1 (fr) Nouvelles 2,4-diamino-5-benzylpyrimidines,leur preparation et leur application en tant que medicaments
FR2303545A1 (fr) Nouvelles pyridones, leur preparation et leur application comme medicaments
FR2332017A1 (fr) Antibiotiques de type thienamycine utiles comme medicaments
BE848385A (fr) Nouvelles phenylpyridylhydantoines substituees et medicament les contenant,

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: STE GENERALE DE RECHERCHES ET D APPLICATIONS

Effective date: 19840604